Corporate Magazine 2012 - Boehringer Ingelheim

usiness year 2012group management reportmoniae, an infectious disease caused by mycoplasmas,with a single injection.Our product metacam® for pain relief when dehorningcalves was also approved throughout Europe in 2012.This decision was based on a study by Ontario VeterinaryCollege at the University of Guelph in Canada, whichanalysed the effect of metacam® on the stress parameters,pain sensitivity and behaviour of calves. The investigationsshowed that calves’ cortisol levels were reducedand they had a significantly lower heartbeat and respiratoryrate after dehorning. metacam® is a non-steroidalanti-inflammatory drug in the oxicam group. The productwas first used for cattle in 1998 and is now approvedin over 40 countries.R&D CooperationsAt the start of 2012, Boehringer Ingelheim, GWT andthe Medical Faculty of the Technical University of Dresden,Germany, signed a five-year research agreement.This cooperation is aimed at obtaining new findings onthe causes of diabetes and the link between raised glucoselevels and the severe complications associated withthe disease. In addition, a four-year cooperation withthe Institute of Molecular Health Sciences and the Instituteof Food, Nutrition and Health of the Swiss FederalInstitute of Technology in Zurich has been entered intoin order to obtain new findings on the development ofdiabetes and obesity. The joint work is focused on examiningthree cell types that could contribute to the onsetof diabetes due to their key role in metabolic homeostasis.In mid-2012, an agreement was reached with FunxionalTherapeutics in which Boehringer Ingelheim acquiredthe global rights to the substance FX125L andthe somatotaxin range. FX125L is a molecule for treatingseveral inflammatory diseases. Its effect has alreadybeen examined in a phase II study. With the agreement,Boehringer Ingelheim has taken over the further research,development and marketing of the substanceFX125L. Furthermore, a cooperation agreement has beenconcluded with the US company Healthrageous, Inc..Boehringer Ingelheim and Healthrageous, Inc., a digitalhealth management company, are working on an innovativebusiness model and, in a pilot study, will be jointlyexamining a lifestyle-changing programme aimed at improvingthe health of patients with type 2 diabetes.The organisation TransCelerate BioPharma, Inc. was alsoestablished by Boehringer Ingelheim and nine otherleading biopharmaceutical companies in the 2012 financialyear. The objective of this joint venture is to meet thechallenges in drug development together and to improvethe quality of clinical studies in order to provide patientswith new medications more quickly.ProductionHuman PharmaceuticalsThe Human Pharmaceuticals production network comprised20 sites in 13 countries in 2012. Spread over theseproduction sites, Boehringer Ingelheim operates 12 pharmaceuticalunits, five chemical units, three biopharmaceuticalunits and one production unit for medical productsworldwide. Our many years of experience at theseproduction sites guarantee a reliable and high-qualityproduct supply using state-of-the-art technology. Ourproduction division is therefore a reliable partner bothfor internal group customers and external industrialcustomers.The chemical and pharmaceutical production sites forproduct launches are grouped together in the Launch &Strategic Products (LSP) division, which forms an interfacebetween our development activities and series production.The division ensures adherence to our high qualityrequirements for new product launches as well as thetechnologically and procedurally challenging manufactureof these innovative products during the first years oftheir life cycle. Our Established Products (ESP) divisionis focused on the manufacture of established products inthe advanced stages of their life cycle, and accounts formore than half of our total production volume. A globalpresence in all growth markets allows us maximum flexibilityin our ESP production network, so that we can reactoptimally to local requirements. We can thereforemanufacture not only our proprietary drugs, but alsoBusiness and operating environment 27